HEOR Services Market Analysis

HEOR Services Market Analysis

In terms of service, the HEOR services market is categorized into market access solutions & reimbursement, economic modeling/evaluation, clinical outcome, real-world data analysis & information systems, and others. The market access solutions & reimbursement segment is speculated to witness growth at more than 14.5% CAGR from 2023-2032. The segment includes tools and services for evidence generation and safeguard patient access to drugs at reasonable prices. The burgeoning drug launches and therapies are also accelerating the demand for market access solutions and reimbursement services.

With respect to the service provider, the health economics & outcomes research (HEOR) services market is divided into consultancy and contract research organizations (CRO). The consultancy segment is anticipated to depict a growth of over 14.5% between 2023 and 2032. The consultants assist businesses with advice and ideas regarding prudent regulatory requirements. Additionally, the preference for consulting services that support decision-making and provide appropriate business solutions is poised to create several prospects for business expansion.
 

In terms of end-use, the HEOR services market is segmented into healthcare providers, biotech/pharma companies, healthcare payers, government organizations, and others. The global market size from the healthcare payers is foreseen to reach USD 1.2 billion in revenue by 2032. This growth is attributed to increasing reliance of healthcare payers on HEOR studies owing to the transition from fee-for-service to value-based reimbursement, increased consumer-driven healthcare, and rising usage of specialty medications & targeted therapies, healthcare payers are pushing healthcare payers to adopt HEOR studies. The development of analytical tools in healthcare IT enables system alignment across several platforms, further impacting the market positively.
 

Regionally, the global HEOR services market is segregated into Europe, Asia Pacific, North America, the Middle East & Africa, and Latin America. Asia Pacific industry is slated to expand at more than 15.5% CAGR over 2023-2032. The region is set to experience rapid growth driven by high R&D funding by regional pharma giants. Additionally, the region's huge population base and favorable regulatory environment contribute to the market's expansion for HEOR services.